BRCA1 and ovarian cancer: In a murine model of BRCA1-deficient ovarian cancer, the use of olaparib to inhibit PARP1 promotes antitumor immunity, especially when it is combined with PD-L1-blocking antibodies, and this action is STING-dependent in mice with tumor xenografts [145].